Secretome Therapeutics Secures PPMD Funding to Advance Duchenne Cardiomyopathy Therapy

According to a recent LinkedIn post from Secretome Therapeutics, the company has been selected to receive $250,000 in funding from Parent Project Muscular Dystrophy via the PPMD Venture Pathways program. The post indicates that this capital is intended to support STM-01, a neonatal cardiac progenitor cell therapy candidate targeting Duchenne-associated cardiomyopathy.

The LinkedIn post suggests growing external validation for Secretome Therapeutics’ platform in the rare disease and cardiomyopathy space, as PPMD is a specialized patient advocacy organization in Duchenne muscular dystrophy. For investors, this non-dilutive funding may modestly extend runway for STM-01 development and signals potential for additional strategic or grant-based support, though it does not yet change the fundamental risk profile typical of early-stage cell therapy programs.